The Medicines Company appoints Tony Kingsley president and chief operating officer
The Medicines Company has appointed Tony Kingsley as president and chief operating officer. Kingsley will help oversee the day-to-day operations of the company and will lead the company’s commercial activities.
Before joining The Medicines Company, Kingsley was executive vice president, Global Commercial Operations at Biogen, where he oversaw the launch of multiple new therapies, including TECFIDERA, an oral treatment for multiple sclerosis, and where his leadership contributed to a period of exceptional growth. Prior to Biogen, Kingsley served as senior vice president and general manager of the Gynecological Surgical Products business at Hologic, and as division president, Diagnostic Products, at Cytyc. Earlier in his career, Kingsley was a Partner at McKinsey & Company focusing on the biotechnology, pharmaceutical and medical device industries.
“Tony brings extensive leadership experience and broad operational expertise developed over a long and enormously successful career. His contributions will be invaluable as the company enters this exciting period and we continue to execute on our strategy to drive growth from our core, high-value assets, while maximizing strategic and operational flexibility,” said Clive Meanwell, M.D., Ph.D., chief executive officer of The Medicines Company. “Tony’s expertise will also enable us to optimize the design of critical clinical trials for our potential blockbuster development products to ensure that trial objectives support the future commercialization of those products.”
Kingsley added, “I am thrilled to join The Medicines Company and look forward to working with Clive and his team of talented, dedicated employees to drive growth while positioning the company to maximize the value of its incredibly-promising R&D pipeline. This is an extraordinary opportunity to be part of a company that carries the promise of profoundly improving and extending the lives of so many, while fundamentally altering the competitive landscape.”